Xenon Pharmaceuticals Inc.
General ticker "XENE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.5B (TTM average)
Xenon Pharmaceuticals Inc. follows the US Stock Market performance with the rate: 45.8%.
Estimated limits based on current volatility of 1.7%: low 62.73$, high 64.80$
Factors to consider:
- Earnings expected soon, date: 2026-08-10 amc
- Total employees count: 370 (+13.1%) as of 2025
- Top business risk factors: Product development failure, Regulatory and compliance, Significant losses, Market competition, Labor/talent shortage/retention
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [31.36$, 62.46$]
- 2026-12-31 to 2027-12-31 estimated range: [26.39$, 54.28$]
Financial Metrics affecting the XENE estimates:
- Negative: with PPE of -10.3 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -7.86 <= 0.30
- Positive: Investing cash flow per share per price, % of 6.14 > -0.65
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 91.88 > 63.79
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term XENE quotes
Long-term XENE plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $7.50MM |
| Operating Expenses | $214.05MM | $279.30MM | $380.57MM |
| Operating Income | $-214.05MM | $-279.30MM | $-373.07MM |
| Non-Operating Income | $31.37MM | $40.88MM | $28.18MM |
| R&D Expense | $167.51MM | $210.39MM | $300.94MM |
| Income(Loss) | $-182.69MM | $-238.42MM | $-344.89MM |
| Taxes | $-0.29MM | $-4.09MM | $1.02MM |
| Net Income(Loss)* | $-182.39MM | $-234.33MM | $-345.91MM |
| Stockholders Equity | $927.92MM | $754.90MM | $581.76MM |
| Assets | $964.80MM | $798.14MM | $633.16MM |
| Operating Cash Flow | $-151.11MM | $-181.39MM | $-279.12MM |
| Capital expenditure | $5.62MM | $3.08MM | $0.80MM |
| Investing Cash Flow | $-111.39MM | $165.00MM | $218.00MM |
| Financing Cash Flow | $353.52MM | $12.13MM | $117.11MM |
| Earnings Per Share** | $-2.73 | $-3.01 | $-4.36 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.